{
  "abstract": "As respiratory paediatricians, we were disappointed to see the negative results reported previously in the AZTEC trial1 as we have found it to be a useful treatment in a range of lung diseases affecting children. Although the effects are modest, there is compelling evidence to show azithromycin is useful in cystic fibrosis,2 3 primary ciliary dyskinesia4 and severe asthma.5 Despite a paucity of evidence, it is also widely used in children with protracted bacterial bronchitis6 as well as in those with bronchiolitis obliterans7 and interstitial lung disease.8",
  "authors": [
    {
      "affiliations": [
        "Royal Stoke University Hospital, Academic Department of Child Health, Newcastle Road, Stoke-on-Trent, UK, ST4 6QG, Staffordshire Children’s Hospital, Stoke-on-Trent, Staffordshire, UK"
      ],
      "name": "Will Carroll"
    },
    {
      "affiliations": [
        "Academic Department of Child Health, Newcastle Road, ST4 6QG, Staffordshire Children’s Hospital, Royal Stoke University Hospital, Stoke-on-Trent, Staffordshire, UK"
      ],
      "name": "James Chapman"
    },
    {
      "affiliations": [
        "Academic Department of Child Health, Staffordshire Children’s Hospital, Royal Stoke University Hospital, Stoke on Trent, UK",
        "Institute of Applied Clinical Sciences, Keele University, Stoke on Trent, UK"
      ],
      "name": "Francis J Gilchrist"
    }
  ],
  "title": "Making sense of azithromycin resistance patterns: what have we learnt and what should we do?",
  "uid": "3a84ac20-0cf8-5391-a76f-26febe5ef658"
}